CLINICAL UPDATES · SEASON 1 · EPISODE 8
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and a major cause of kidney failure in mid-life. This Clinical Update covers how cyst growth drives the disease, how progression risk is assessed, and the modern treatment landscape — blood-pressure control, surveillance, and the first therapy that slows cyst growth.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
MedicalVideos Clinical Updates is an educational series produced with full editorial independence. If an episode is sponsor-funded, that funding is labelled on the episode page and on the series hub.
The update
The clinical picture
In ADPKD, faults in the polycystin proteins disturb tubular cell signalling, so fluid-filled cysts form and grow throughout both kidneys from early life. Kidneys enlarge steadily — sometimes to several times normal size — while function is preserved for decades by the surviving tissue, then declines. The disease is rarely only about kidneys: liver cysts are very common, heart valve changes and hernias occur more often, and a minority of patients harbour brain aneurysms. Pain, urinary infections, kidney stones, and blood in the urine are the usual day-to-day problems long before kidney failure arrives, typically in mid-adult life for the common form.
The current landscape
The therapeutic turning point was the arrival of vasopressin V2 receptor blockade (tolvaptan), the first treatment shown to slow kidney growth and functional decline in adults at risk of rapid progression. It comes with real burdens — very large urine volumes, thirst, and a requirement for liver monitoring — so selection is careful and shared. Identifying rapid progressors uses the Mayo imaging classification, which grades total kidney volume against age and height. Blood-pressure control with renin–angiotensin blockade remains foundational for everyone, and salt restriction supports it. Research continues into metabolic and signalling-pathway approaches, but none has yet joined standard care.
In practice
Diagnosis rests on imaging — ultrasound in most adults, MRI when precise volumes are needed — interpreted against age and family history, with genetic testing reserved for uncertain or early cases. Baseline assessment records kidney volume, blood pressure, kidney function, and urine findings, and asks about family history of aneurysm. Monitoring follows blood pressure, eGFR trend, and symptoms; imaging is repeated when it would change management, such as before starting progression-slowing therapy. Counselling covers inheritance — each child has a one-in-two chance — family screening, insurance implications of genetic information, and pregnancy planning. Nephrology follow-up is long-term and usually shared with primary care.
When to escalate
Escalate urgently for fever with flank pain — cyst infection can be hard to reach with antibiotics and may need drainage. Sudden severe headache in a patient with ADPKD is an emergency because of the aneurysm association. Gross hematuria after trauma, uncontrolled pain, or signs of cyst rupture also need prompt review. Outside emergencies, escalate when imaging shows rapid kidney growth, when blood pressure escapes control despite treatment, or when kidney function declines faster than expected — each may change the treatment conversation.
Common questions
Should children of a parent with ADPKD be screened?
Usually not at first — adult children are typically offered screening as adults, when results can change care and they can decide for themselves. Ultrasound is the usual first test, with MRI or genetic testing in selected situations, arranged through the treating team or a genetics service.
Does everyone with ADPKD need the cyst-slowing medicine?
Only in some patients. The medicines that slow cyst growth (vasopressin receptor blockers) suit selected adults with evidence of rapid progression, because they require intensive monitoring of urine output, thirst, and liver tests. Many patients do well with blood-pressure control and surveillance alone.
Do kidney cysts in ADPKD need to be drained or removed?
Most cysts are watched, not drained. Intervention is considered for cysts that become infected, bleed repeatedly, cause severe pain, or are suspected of something more serious. Infected cysts are the main emergency and may need specific antibiotics and drainage.
What about brain aneurysms in ADPKD?
Aneurysms occur in a minority of patients, more often with a family history of aneurysm or rupture. Screening is targeted to those with that history or other risk features, rather than offered to everyone — a decision made individually with the treating team.
More in Glomerular & Inherited Disease
Related
Related reading
Sources
- Autosomal Dominant Polycystic Kidney Disease (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- What Is PKD? (PKD Foundation)
- Polycystic Kidney Disease (MedlinePlus Genetics, US National Library of Medicine)
This Clinical Update is educational content for clinicians and informed patients. It is not medical advice and does not replace the judgment of the treating team. Drug classes are discussed in general terms only; prescribing decisions, doses, and monitoring belong with the patient's own clinicians. Surveillance schedules and blood-pressure targets in ADPKD are individualised; family screening decisions should be made with the treating team.